Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of SOF/VEL/VOX and Norgestimate/Ethinyl Estradiol
NCT02533427Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Area Under the Concentration-Time Curve Over the Dosing Interval at Day 42, Maximum Observed Plasma Concentration at Day 42 and 1 more. Started Oct 2015; status: completed.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02533427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533427.